Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) have received a consensus recommendation of “Hold” from the six research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $4.81.

Several brokerages recently weighed in on LIFE. Zacks Investment Research downgraded aTyr Pharma from a “buy” rating to a “hold” rating and set a $5.25 target price on the stock. in a research note on Thursday, September 28th. Piper Jaffray Companies began coverage on aTyr Pharma in a research note on Thursday, September 7th. They set an “overweight” rating and a $7.00 target price on the stock. BMO Capital Markets set a $4.00 target price on aTyr Pharma and gave the stock a “hold” rating in a research note on Tuesday, August 15th. Finally, ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th.

aTyr Pharma (LIFE) opened at $3.75 on Tuesday. aTyr Pharma has a fifty-two week low of $2.10 and a fifty-two week high of $6.50. The company has a current ratio of 9.49, a quick ratio of 9.49 and a debt-to-equity ratio of 0.17.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.07. analysts anticipate that aTyr Pharma will post -1.95 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “aTyr Pharma, Inc. (LIFE) Given Average Recommendation of “Hold” by Brokerages” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/21/atyr-pharma-inc-life-given-average-recommendation-of-hold-by-brokerages.html.

In other aTyr Pharma news, CEO John Mendlein purchased 37,736 shares of aTyr Pharma stock in a transaction that occurred on Thursday, August 31st. The stock was bought at an average price of $2.65 per share, with a total value of $100,000.40. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Paul Schimmel acquired 94,336 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were purchased at an average price of $2.65 per share, with a total value of $249,990.40. Following the completion of the purchase, the director now owns 40,440 shares in the company, valued at approximately $107,166. The disclosure for this purchase can be found here. Corporate insiders own 33.30% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Renaissance Technologies LLC grew its position in shares of aTyr Pharma by 1.8% in the first quarter. Renaissance Technologies LLC now owns 38,800 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 700 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in aTyr Pharma by 44.1% in the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after acquiring an additional 25,676 shares during the last quarter. Victory Capital Management Inc. acquired a new position in aTyr Pharma in the third quarter valued at approximately $455,000. Finally, Artal Group S.A. acquired a new position in aTyr Pharma in the third quarter valued at approximately $1,263,000. Institutional investors own 40.66% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.